Seattle, United States
Icogenex Corporation is a Seattle-based privately held biotechnology company founded in 1995, specializing in identifying and developing therapeutic compounds for the treatment of human disease. In 2003, the company was renamed Icogenex. The company's operations have been financed through investments, contracts, and grant support from the National Institutes of Health. Notably, Icogenex has received 13 SBIR Phase I awards, 4 SBIR Phase II awards, an R21, and an R01 award.
The company has successfully completed 10 contract research projects with biotechnology and pharmaceutical companies, demonstrating a proven track record of meeting drug development milestones and timelines. Collaborative projects with HemeBiotech (now called Zymenex) resulted in significant achievements, including a successful Phase I clinical trial, successful preclinical trial, and a Phase II clinical trial that ultimately led to the sale of the project by Zymenex to Shire PLC for $135 million.
Icogenex Corporation's focus on developing therapeutic compounds and its history of successful collaborations and achievements position it as a promising player in the biotechnology, healthcare, and pharmaceutical industries.
